1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Pancreatic	_	_	JJ	_	_	_	_	_
2	cancer	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	PC	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	one	_	_	CD	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	most	_	_	RBS	_	_	_	_	_
12	aggressive	_	_	JJ	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	therapeutically	_	_	RB	_	_	_	_	_
15	ineffective	_	_	JJ	_	_	_	_	_
16	malignant	_	_	JJ	_	_	_	_	_
17	cancers	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Mortality	_	_	NN	_	_	_	_	_
2	due	_	_	JJ	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	PC	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	fourth	_	_	JJ	_	_	_	_	_
7	among	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	various	_	_	JJ	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	types	_	_	NNS	_	_	_	_	_
12	worldwide	_	_	RB	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2018	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	458,918	_	_	CD	_	_	_	_	_
5	new	_	_	JJ	_	_	_	_	_
6	cases	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	432,242	_	_	CD	_	_	_	_	_
9	deaths	_	_	NNS	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	PC	_	_	NNP	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	recorded	_	_	VBN	_	_	_	_	_
14	worldwide	_	_	RB	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	primary	_	_	JJ	_	_	_	_	_
5	reasons	_	_	NNS	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	high	_	_	JJ	_	_	_	_	_
9	mortality	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	difficulty	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	early	_	_	JJ	_	_	_	_	_
15	diagnosis	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	disease	_	_	NN	_	_	_	_	_
19	because	_	_	IN	_	_	_	_	_
20	pancreas	_	_	NN	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	behind	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	stomach	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	patient	_	_	NN	_	_	_	_	_
28	shows	_	_	VBZ	_	_	_	_	_
29	general	_	_	JJ	_	_	_	_	_
30	symptoms	_	_	NNS	_	_	_	_	_
31	such	_	_	JJ	_	_	_	_	_
32	as	_	_	IN	_	_	_	_	_
33	digestive	_	_	JJ	_	_	_	_	_
34	problems	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	abdominal	_	_	JJ	_	_	_	_	_
37	pain	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	weight	_	_	NN	_	_	_	_	_
41	loss	_	_	NN	_	_	_	_	_
42	before	_	_	IN	_	_	_	_	_
43	metastasis	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	More	_	_	JJR	_	_	_	_	_
2	than	_	_	IN	_	_	_	_	_
3	80	_	_	CD	_	_	_	_	_
4	%	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	PC	_	_	NN	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	show	_	_	VBP	_	_	_	_	_
9	metastasis	_	_	NN	_	_	_	_	_
10	at	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	time	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	diagnosis	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	various	_	_	JJ	_	_	_	_	_
3	therapeutic	_	_	JJ	_	_	_	_	_
4	methods	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	5-year	_	_	JJ	_	_	_	_	_
8	survival	_	_	NN	_	_	_	_	_
9	rate	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	PC	_	_	NNP	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	only	_	_	RB	_	_	_	_	_
14	8	_	_	CD	_	_	_	_	_
15	%	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	PC	_	_	NNP	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	projected	_	_	VBN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	be	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	second	_	_	JJ	_	_	_	_	_
24	leading	_	_	VBG	_	_	_	_	_
25	cause	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	cancer	_	_	NN	_	_	_	_	_
28	deaths	_	_	NNS	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	2030	_	_	CD	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Gemcitabine	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	Gem	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	approved	_	_	VBN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	first-line	_	_	JJ	_	_	_	_	_
10	chemotherapeutic	_	_	JJ	_	_	_	_	_
11	drug	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	PC	_	_	NN	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	response	_	_	NN	_	_	_	_	_
5	rate	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	Gem	_	_	NNP	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	PC	_	_	NNP	_	_	_	_	_
10	patients	_	_	NNS	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	only	_	_	RB	_	_	_	_	_
13	12	_	_	CD	_	_	_	_	_
14	%	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	most	_	_	JJS	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	resistant	_	_	JJ	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	Gem	_	_	NNP	_	_	_	_	_
22	within	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	few	_	_	JJ	_	_	_	_	_
25	weeks	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Less	_	_	JJR	_	_	_	_	_
2	than	_	_	IN	_	_	_	_	_
3	25	_	_	CD	_	_	_	_	_
4	%	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	PC	_	_	NNP	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	benefit	_	_	VBP	_	_	_	_	_
9	from	_	_	IN	_	_	_	_	_
10	Gem	_	_	NN	_	_	_	_	_
11	treatment	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	median	_	_	JJ	_	_	_	_	_
15	overall	_	_	JJ	_	_	_	_	_
16	survival	_	_	NN	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	only	_	_	RB	_	_	_	_	_
19	6	_	_	CD	_	_	_	_	_
20	months	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	overcome	_	_	VB	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	limitations	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	Gem	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	combinatorial	_	_	JJ	_	_	_	_	_
11	regimens	_	_	NNS	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	folinic	_	_	JJ	_	_	_	_	_
15	acid	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	5-fluorouracil	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	irinotecan	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	oxaliplatin	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	FOLFIRINOX	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	have	_	_	VBP	_	_	_	_	_
26	been	_	_	VBN	_	_	_	_	_
27	widely	_	_	RB	_	_	_	_	_
28	used	_	_	VBN	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	treat	_	_	VB	_	_	_	_	_
31	PC	_	_	NN	_	_	_	_	_
32	patients	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_
34	FOLFIRINOX	_	_	NNP	_	_	_	_	_
35	presents	_	_	VBZ	_	_	_	_	_
36	higher	_	_	JJR	_	_	_	_	_
37	response	_	_	NN	_	_	_	_	_
38	rates	_	_	NNS	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	its	_	_	PRP$	_	_	_	_	_
41	median	_	_	JJ	_	_	_	_	_
42	overall	_	_	JJ	_	_	_	_	_
43	survival	_	_	NN	_	_	_	_	_
44	is	_	_	VBZ	_	_	_	_	_
45	nearly	_	_	RB	_	_	_	_	_
46	12	_	_	CD	_	_	_	_	_
47	months	_	_	NNS	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	regimen	_	_	NN	_	_	_	_	_
5	shows	_	_	VBZ	_	_	_	_	_
6	considerable	_	_	JJ	_	_	_	_	_
7	adverse	_	_	JJ	_	_	_	_	_
8	effects	_	_	NNS	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	lower	_	_	JJR	_	_	_	_	_
12	blood	_	_	NN	_	_	_	_	_
13	counts	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	fever	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	infection	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	diarrhea	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	weight	_	_	NN	_	_	_	_	_
23	loss	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	development	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	new	_	_	JJ	_	_	_	_	_
6	chemotherapeutic	_	_	JJ	_	_	_	_	_
7	drugs	_	_	NNS	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	overcome	_	_	VB	_	_	_	_	_
11	chemoresistance	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	have	_	_	VB	_	_	_	_	_
14	less	_	_	RBR	_	_	_	_	_
15	adverse	_	_	JJ	_	_	_	_	_
16	effects	_	_	NNS	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	needed	_	_	VBN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Oat	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	Avena	_	_	FW	_	_	_	_	_
4	sativa	_	_	FW	_	_	_	_	_
5	L.	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	important	_	_	JJ	_	_	_	_	_
10	cereal	_	_	JJ	_	_	_	_	_
11	crop	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	family	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	Poaceae	_	_	NNP	_	_	_	_	_
17	grown	_	_	VBN	_	_	_	_	_
18	worldwide	_	_	RB	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Oats	_	_	NNS	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	various	_	_	JJ	_	_	_	_	_
4	advantages	_	_	NNS	_	_	_	_	_
5	;	_	_	:	_	_	_	_	_
6	they	_	_	PRP	_	_	_	_	_
7	require	_	_	VBP	_	_	_	_	_
8	less	_	_	JJR	_	_	_	_	_
9	nutrients	_	_	NNS	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	grow	_	_	VB	_	_	_	_	_
12	than	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	wheat	_	_	NN	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	corn	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Additionally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	as	_	_	IN	_	_	_	_	_
4	people	_	_	NNS	_	_	_	_	_
5	become	_	_	VBP	_	_	_	_	_
6	more	_	_	RBR	_	_	_	_	_
7	aware	_	_	JJ	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	their	_	_	PRP$	_	_	_	_	_
10	health	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	more	_	_	JJR	_	_	_	_	_
13	people	_	_	NNS	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	consuming	_	_	VBG	_	_	_	_	_
16	oats	_	_	NNS	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	form	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	oatmeal	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	granola	_	_	NN	_	_	_	_	_
24	bars	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	cookies	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	beverages	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	revealed	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	oats	_	_	NNS	_	_	_	_	_
7	possess	_	_	VBP	_	_	_	_	_
8	beneficial	_	_	JJ	_	_	_	_	_
9	health	_	_	NN	_	_	_	_	_
10	effects	_	_	NNS	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	aging	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	oxidant	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	liver	_	_	NN	_	_	_	_	_
19	injury	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	hypercholesterolemia	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	gastrointestinal	_	_	JJ	_	_	_	_	_
25	problems	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	ethanol	_	_	NN	_	_	_	_	_
9	extract	_	_	NN	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	oat	_	_	NN	_	_	_	_	_
13	bran	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	OBE	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	PC	_	_	NNP	_	_	_	_	_
19	were	_	_	VBD	_	_	_	_	_
20	investigated	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	vitro	_	_	FW	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	confirm	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	anti-cancer	_	_	JJ	_	_	_	_	_
5	effect	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	OBE	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	PC	_	_	NN	_	_	_	_	_
10	cell	_	_	NN	_	_	_	_	_
11	viability	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	colony	_	_	NN	_	_	_	_	_
14	formation	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	cell	_	_	NN	_	_	_	_	_
17	cycle	_	_	NN	_	_	_	_	_
18	distribution	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	apoptosis	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	proteins	_	_	NNS	_	_	_	_	_
24	were	_	_	VBD	_	_	_	_	_
25	evaluated	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	combination	_	_	NN	_	_	_	_	_
5	effects	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	Gem	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	OBE	_	_	NNP	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	PC	_	_	NNP	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	acquired	_	_	VBN	_	_	_	_	_
15	resistance	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	Gem	_	_	NNP	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	investigated	_	_	VBN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	test	_	_	VB	_	_	_	_	_
22	if	_	_	IN	_	_	_	_	_
23	combination	_	_	NN	_	_	_	_	_
24	therapy	_	_	NN	_	_	_	_	_
25	could	_	_	MD	_	_	_	_	_
26	overcome	_	_	VB	_	_	_	_	_
27	drug	_	_	NN	_	_	_	_	_
28	resistance	_	_	NN	_	_	_	_	_
29	developed	_	_	VBN	_	_	_	_	_
30	during	_	_	IN	_	_	_	_	_
31	cancer	_	_	NN	_	_	_	_	_
32	treatment	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_

